The company is not selling any shares of its common stock under this prospectus and will not receive any of the proceeds from the sale of the ...

“2024 represented the strongest financial and strategic performance in our history including more than 30% revenue growth, and a 35% reduction ...

ClearPoint Neuro Inc (CLPT) reports a 31% revenue increase, enhanced gross margins, and strategic global expansions, despite facing operational challenges.

Alzamend Neuro , Inc. (NASDAQ ... for an equal number of Series C Convertible Preferred Stock, along with the sale of up to 500 shares of Series C Preferred Stock and corresponding warrants ...